OtherBASIC SCIENCE INVESTIGATIONS
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
Robert M. Sharkey, Habibe Karacay, Christine R. Johnson, Samuel Litwin, Edmund A. Rossi, William J. McBride, Chien-Hsing Chang and David M. Goldenberg
Journal of Nuclear Medicine March 2009, 50 (3) 444-453; DOI: https://doi.org/10.2967/jnumed.108.058602
Robert M. Sharkey
Habibe Karacay
Christine R. Johnson
Samuel Litwin
Edmund A. Rossi
William J. McBride
Chien-Hsing Chang
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 50, Issue 3
March 2009
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
Robert M. Sharkey, Habibe Karacay, Christine R. Johnson, Samuel Litwin, Edmund A. Rossi, William J. McBride, Chien-Hsing Chang, David M. Goldenberg
Journal of Nuclear Medicine Mar 2009, 50 (3) 444-453; DOI: 10.2967/jnumed.108.058602
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
Robert M. Sharkey, Habibe Karacay, Christine R. Johnson, Samuel Litwin, Edmund A. Rossi, William J. McBride, Chien-Hsing Chang, David M. Goldenberg
Journal of Nuclear Medicine Mar 2009, 50 (3) 444-453; DOI: 10.2967/jnumed.108.058602
Jump to section
Related Articles
Cited By...
- Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
- A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers
- Differential Effects of Predosing on Tumor and Tissue Uptake of an 111In-Labeled Anti-TENB2 Antibody-Drug Conjugate
- Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
- Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
- A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy